ORIC Pharmaceuticals Inc Dossier - Source-backed chat

ORIC Pharmaceuticals Inc

ORICNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.98

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $12.52Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $1.3B

Enterprise Value $1.3B

Shares Outstanding 103.7M diluted

Next Earnings Date10 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Oric Pharmaceuticals is a highly promising clinical-stage oncology company focused on overcoming therapeutic resistance in cancer. The company's lead programs, rinzimetostat (ORIC-944) and enozertinib (ORIC-114), have demonstrated potential best-in-class clinical profiles in prostate and lung cancers, respectively. Backed by a robust cash runway extending into the second half of 2028, Oric is well-positioned to advance its pipeline through critical registrational milestones, including the initiation of the Phase 3 Himalayas-1 trial for rinzimetostat in 1H 2026 and multiple key data readouts in 2H 2026.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets13 analysts · as of 18 Aug 2026

Low · most bearish analyst$14.00

Mean target$21.00

High · most bullish analyst$27.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$14.00

The Phase 3 Himalayas-1 trial faces enrollment delays or safety concerns, and the 2H 2026 clinical readouts for enozertinib fail to show differentiation from competitors. High cash burn accelerates, forcing the company to raise capital under unfavorable market conditions, leading to significant shareholder dilution and a downward re-rating of the stock.

Base CaseCentral scenario

$21.00

Matches the consensus mean

Oric successfully initiates the Phase 3 Himalayas-1 trial for rinzimetostat in 1H 2026 and reports competitive clinical data for both lead programs in 2H 2026. The cash runway remains secure into 2028, allowing the company to execute its clinical plans without immediate dilutive financing. The stock moves steadily toward the consensus analyst price target as clinical milestones are met.

Bull CaseUpside scenario

$27.00

Rinzimetostat demonstrates superior radiographic progression-free survival (rPFS) in the Phase 3 Himalayas-1 trial compared to standard-of-care therapies, establishing it as a best-in-class PRC2 inhibitor. Concurrently, enozertinib delivers outstanding first-line monotherapy and combination data in NSCLC, triggering a lucrative co-development partnership with a major pharmaceutical company. Rapid clinical progress and strong validation drive the stock toward the high end of analyst targets.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong cash position of $290.2 million in current assets (as of March 31, 2026) providing a runway into 2H 2028, past major clinical readouts.
Lead candidate rinzimetostat (ORIC-944) is advancing to a Phase 3 registrational trial (Himalayas-1) in mCRPC, supported by strong Phase 1b combination data showing superior rPFS compared to historical standard-of-care.
Enozertinib (ORIC-114) has shown highly competitive systemic and brain-penetrant activity in NSCLC with EGFR exon 20 and PACC mutations, with key data readouts expected in 2H 2026.
Established clinical collaborations with industry giants like Pfizer, Bayer, and Johnson & Johnson validate Oric's scientific approach and pipeline potential.

Key Investment Risks

Clinical-stage risk: The company is pre-revenue and entirely dependent on the clinical and regulatory success of its pipeline candidates.
Execution risk: Potential delays in enrolling the 600-patient Phase 3 Himalayas-1 trial could push back development timelines.
Competitive landscape: The oncology space is highly competitive, with multiple approved therapies and pipeline candidates targeting similar indications.
Dilution risk: Despite a strong cash runway, future clinical development and commercialization efforts will require substantial capital, potentially leading to equity dilution.

Thesis Invalidation Triggers

Failure or termination of the Phase 3 Himalayas-1 trial for rinzimetostat due to lack of efficacy or unacceptable safety signals.
Disappointing clinical data readouts for enozertinib in 2H 2026 that fail to demonstrate competitive advantages over existing or emerging therapies.
A significant reduction in cash runway due to unexpected operational cost overruns or clinical trial delays, forcing premature dilutive financing.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.